10/562126 JC10 Rec'd PCT/PTO 23 DEC 2005

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q92342

Takayuki MARUYAMA, et al.

Appln. No.: Based on PCT/JP04/009362

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: December 23, 2005

Examiner: Unknown

For:

REMEDY FOR URINARY TRACT DISEASES

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith via CD-ROM, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

10 /562126 JC10 Rec'd PCT/PTO 23 DEC 2005

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: Based on PCT/JP04/009362

Attorney Docket No.: Q92342

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant encloses herewith a copy of a Communication from a

foreign patent office in a counterpart application citing such documents (International Search

Report for PCT/JP04/009362 dated November 2, 2004), together with an English-language

version (if not already included) of at least that portion of the Communication indicating the

degree of relevance found by the foreign patent office.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,

July Boland

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: December 23, 2005

Mark Boland

Registration No. 32,197

2

JC10 Rec'd PCT/PTQ 23 DEC 2005 MODIFIED PTO/SB/08 A & B (06-03)

Substitute for Form 1449 A & B/PTO				Complete if Congress 62126		
				Application Number	Based on PCT/JP04/009362	
INFOI	RMATION	DISCLOS	SURE	Confirmation Number	Unknown	
	EMENT B			Filing Date	December 23, 2005	
<u> </u>	55			First Named Inventor	Takayuki MARUYAMA	
` (use	as many shee	ts as necessai	rv)	Art Unit	Unknown	
(**************************************				Examiner Name	Unknown	
Sheet	1	of	1	Attorney Docket Number	Q92342	

U.S. PATENT DOCUMENTS						
Examiner Initials*		Document N	Number	Publication Date MM-DD-YYYY		
	Cite No. ¹	Number	Kind Code ² (if known)		Name of Patentee or Applicant of Cited Document	
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US				
		US				

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Fo	Foreign Patent Document			Name of Patentee or	
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Translation ⁶
		wo	02/72564	A1	09-19-2002	ONO PHARM CO LTD	
		wo	03/16254	A1	02-27-2003	ONO PHARM CO LTD	
				1			
		† <u>-</u>			-		
		7	† 				

NON PATENT LITERATURE DOCUMENTS					
Examiner Cite Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
-					

		· · · · · · · · · · · · · · · · · · ·
Examiner Signature	Date Considered	
<u> </u>		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.